Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2486-2494

  Mielke, Michelle M ^a   Haughey, Norman J ^b   Bandaru, Veera V R ^b   Zetterberg, Henrik ^c,d   Blennow, Kaj ^c,d   Andreasson, Ulf ^c,d   Johnson, Sterling C ^e,f   Gleason, Carey E ^e,f   Blazel, Hanna M ^e   Puglielli, Luigi ^e,f   Sager, Mark A ^e   Asthana, Sanjay ^e,f   Carlsson, Cynthia M ^e,f  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^f Education and Clinical Center   (United States)

Author keywords

Alzheimer's disease; Beta amyloid; Ceramide; Cerebrospinal fluid; Sphingolipids; Sphingomyelin; Tau

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[X-38]; CERAMIDE; P TAU181 PROTEIN; SPHINGOLIPID; SPHINGOMYELIN; T TAU PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; APOLIPOPROTEIN E;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; COGNITION; FEMALE; GENOTYPE; HIGH RISK POPULATION; HUMAN; IN VIVO STUDY; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; CEREBROSPINAL FLUID; GENETICS; PSYCHOLOGY; RISK;

ADULT; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CERAMIDES; COGNITION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; RISK; SPHINGOMYELINS; TAU PROTEINS;

EID: 84922957221     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.05.019     Document Type: Article

References (50)

1. Benton A., Hamsher K. Multilingual Aphasia Examination 1989, AJA Associates, Iowa City, IA.
2. Brandt J. The Hopkins Verbal Learning Test: development of a new memory test with six equivalent forms. Clin. Neuropsychol. 1991, 5:125-142.
3. Chalfant C.E., Kishikawa K., Mumby M.C., Kamibayashi C., Bielawska A., Hannun Y.A. Long chain ceramides activate protein phosphatase-1 and protein phosphatase-2A. Activation is stereospecific and regulated by phosphatidic acid. J.Biol. Chem. 1999, 274:20313-20317.
4. Contreras F.X., Ernst A.M., Haberkant P., Bjorkholm P., Lindahl E., Gonen B., Tischer C., Elofsson A., von Heijne G., Thiele C., Pepperkok R., Wieland F., Brugger B. Molecular recognition of a single sphingolipid species by a protein's transmembrane domain. Nature 2012, 481:525-529.
5. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., Troncoso J.C., Mattson M.P. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A 2004, 101:2070-2075.
6. D'Elia L.F., Satz P., Uchiyama C.L., White T. Color Trails Test: Professional Manual 1996, Psychological Assessment Resources, Odessa, FL.
7. Dobrowsky R.T., Kamibayashi C., Mumby M.C., Hannun Y.A. Ceramide activates heterotrimeric protein phosphatase 2A. J.Biol. Chem. 1993, 268:15523-15530.
8. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J.Psychiatr. Res. 1975, 12:189-198.
9. Gatt S., Bierman E.L. Sphingomyelin suppresses the binding and utilization of low density lipoproteins by skin fibroblasts. J.Biol. Chem. 1980, 255:3371-3376.
10. Goedert M., Jakes R., Qi Z., Wang J.H., Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase. J.Neurochem. 1995, 65:2804-2807.
11. Gong C.X., Grundke-Iqbal I., Iqbal K. Dephosphorylation of Alzheimer's disease abnormally phosphorylated tau by protein phosphatase-2A. Neuroscience 1994, 61:765-772.
12. Goodman Y., Mattson M.P. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J.Neurochem. 1996, 66:869-872.
13. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., Tschape J.A., De Strooper B., Muller U., Shen J., Hartmann T. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 2005, 7:1118-1123.
14. Han X., Rozen S., Boyle S.H., Hellegers C., Cheng H., Burke J.R., Welsh-Bohmer K.A., Doraiswamy P.M., Kaddurah-Daouk R. Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011, 6:e21643.
15. Hannun Y.A. Functions of ceramide in coordinating cellular responses to stress. Science 1996, 274:1855-1859.
16. Haughey N.J., Bandaru V.V., Bae M., Mattson M.P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 2010, 1801:878-886.
17. Haughey N.J., Cutler R.G., Tamara A., McArthur J.C., Vargas D.L., Pardo C.A., Turchan J., Nath A., Mattson M.P. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 2004, 55:257-267.
18. He X., Huang Y., Li B., Gong C.X., Schuchman E.H. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 2010, 31:398-408.
19. Hubley A.M. Modification of the Taylor Complex Figure: A Comparable Figureto the Rey-Osterrieth Figure? Edgeworth Series in Quantitative Behavioural Science, Paper No. ESQBS-96-7 1996, University of Northern British Columbia, Prince George, B.C., Canada.
20. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013, 12:207-216.
21. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010, 9:119-128.
22. Jack C.R., Wiste H.J., Weigand S.D., Knopman D.S., Lowe V., Vemuri P., Mielke M.M., Jones D.T., Senjem M.L., Gunter J.L., Gregg B.E., Pankratz V.S., Petersen R.C. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013, 81:1732-1740.
23. Kalvodova L., Kahya N., Schwille P., Ehehalt R., Verkade P., Drechsel D., Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids invitro. J.Biol. Chem. 2005, 280:36815-36823.
24. Clinical Neuropsychology 1963, Saunders, New York. H. Kløve (Ed.).
25. Kluger A., Ferris S.H., Golomb J., Mittelman M.S., Reisberg B. Neuropsychological prediction of decline to dementia in nondemented elderly. J.Geriatr. Psychiatry Neurol. 1999, 12:168-179.
26. Kosicek M., Zetterberg H., Andreasen N., Peter-Katalinic J., Hecimovic S. Elevated cerebrospinal fluid sphingomyelin levels in prodromal Alzheimer's disease. Neurosci. Lett. 2012, 516:302-305.
27. Lee J.T., Xu J., Lee J.M., Ku G., Han X., Yang D.I., Chen S., Hsu C.Y. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J.Cell Biol. 2004, 164:123-131.
28. Malec J.F., Ivnik R.J., Smith G.E., Tangalos E.G., Petersen R.C., Kokmen E., Kurland L.T. Visual spatial learning test: normative data and further validation. Psychol. Assess. 1997, 4:433-441.
29. Mattson M.P., Cutler R.G., Jo D.G. Alzheimer peptides perturb lipid-regulating enzymes. Nat. Cell Biol. 2005, 7:1045-1047.
30. Mielke M.M., Bandaru V.V., Haughey N.J., Rabins P.V., Lyketsos C.G., Carlson M.C. Serum sphingomyelins and ceramides are early predictors of memory impairment. Neurobiol. Aging 2010, 31:17-24.
31. Mielke M.M., Bandaru V.V.R., Xia J., Haughey N.J., Fried L.P., Yasar S., Albert M., Varma V., Harris G., Schneider E.G., Rabins P.V., Bandeen-Roche K., Lyketsos C.G., Carlson M.C. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology 2012, 79:633-641.
32. Mielke M.M., Haughey N.J. Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?. Clin. Lipidol. 2012, 7:525-536.
33. Mielke M.M., Haughey N.J., Bandaru V.V., Weinberg D.D., Darby E., Zaidi N., Pavlik V., Doody R.S., Lyketsos C.G. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. J.Alzheimers Dis. 2011, 27:259-269.
34. Mielke M.M., Haughey N.J., Ratnam Bandaru V.V., Schech S., Carrick R., Carlson M.C., Mori S., Miller M.I., Ceritoglu C., Brown T., Albert M., Lyketsos C.G. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimer's Dement. 2010, 6:378-385.
35. Mukhopadhyay A., Saddoughi S.A., Song P., Sultan I., Ponnusamy S., Senkal C.E., Snook C.F., Arnold H.K., Sears R.C., Hannun Y.A., Ogretmen B. Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J. 2009, 23:751-763.
36. Olsson A., Vanderstichele H., Andreasen N., De Meyer G., Wallin A., Holmberg B., Rosengren L., Vanmechelen E., Blennow K. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem. 2005, 51:336-345.
37. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin. Lab 2002, 48:171-180.
38. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J.Biol. Chem. 2003, 278:19777-19783.
39. Quinn P.J., Wolf C. The liquid-ordered phase in membranes. Biochim. Biophys. Acta 2009, 1788:33-46.
40. Reiman E.M., Quiroz Y.T., Fleisher A.S., Chen K., Velez-Pardo C., Jimenez-Del-Rio M., Fagan A.M., Shah A.R., Alvarez S., Arbelaez A., Giraldo M., Acosta-Baena N., Sperling R.A., Dickerson B., Stern C.E., Tirado V., Munoz C., Reiman R.A., Huentelman M.J., Alexander G.E., Langbaum J.B., Kosik K.S., Tariot P.N., Lopera F. Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol. 2012, 11:1048-1056.
41. Ruff R.M., Evans R.W., Light R.H. Automatic detection vs controlled search: a paper-and-pencil approach. Percept. Mot. Skills 1986, 62:407-416.
42. Sager M.A., Hermann B., La Rue A. Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. J.Geriatr. Psychiatry Neurol. 2005, 18:245-249.
43. Satoi H., Tomimoto H., Ohtani R., Kitano T., Kondo T., Watanabe M., Oka N., Akiguchi I., Furuya S., Hirabayashi Y., Okazaki T. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130:657-666.
44. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
45. Simons K., Vaz W.L. Model systems, lipid rafts, and cell membranes. Annu. Rev. Biophys. Biomol. Struct. 2004, 33:269-295.
46. Slotte J.P., Bierman E.L. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem. J. 1988, 250:653-658.
47. Spreen O., Strauss E. ACompendium of Neuropsychological Tests 1998, Oxford University Press, New York. second ed.
48. Tamboli I.Y., Hampel H., Tien N.T., Tolksdorf K., Breiden B., Mathews P.M., Saftig P., Sandhoff K., Walter J. Sphingolipid storage affects autophagic metabolism of the amyloid precursor protein and promotes Abeta generation. J.Neurosci. 2011, 31:1837-1849.
49. Wechsler D. WAIS-R Wechsler Adult Intelligence Scale-III 1991, Psychological Corporation, San Antonio, TX. third ed.
50. Wechsler D. Wechsler Memory Scale-III 1997, Psychological Corporation, San Antonio, TX. third ed.